Sarcotropin: A Homeopathic Growth Hormone Support Formulation for Sarcopenia

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to Sarcotropin. Sarcotropin is not FDA-approved for any indication. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

The marketing around Sarcotropin leans heavily on a real and serious problem: the progressive loss of muscle mass with aging. Sarcopenia is well documented, its mechanisms are understood, and the GH-IGF-1 axis genuinely declines with age. The question is whether an oral amino acid blend can meaningfully restore it. The answer, once you move past the brand literature and into the broader research record, is more complicated than the product's claims suggest.

This article examines what Sarcotropin is, what it contains, what the sponsored and independent research shows about its active ingredients, and how it compares to prescription growth hormone-releasing hormone analogs with far stronger evidence bases.

Key Takeaways

• Regulatory Status: As of April 2026, Sarcotropin is marketed as a "medical food" by Targeted Medical Pharma (TMP). It is not FDA-approved as a drug, not classified as a bulk drug substance for compounding, and not subject to the same efficacy and safety review process as prescription medications.
• Research Stage: Three industry-sponsored, open-label, uncontrolled studies with TMP investigators; no placebo-controlled RCT has been published. Independent evidence for the active ingredients in the context of GH elevation in older adults is largely negative.
• Availability: Sarcotropin is sold by Targeted Medical Pharma and Physician Therapeutics. Superpower does not offer this product.
• What it is: A branded oral blend of amino acids (primarily arginine, lysine, and glutamine) combined with polyphenols and sold as a supplement to support growth hormone levels in adults with sarcopenia.
• What the evidence shows: As of April 2026, no placebo-controlled RCT of Sarcotropin has been published. The single most relevant independent trial tested oral arginine-lysine (the Sarcotropin combination) in older men and found no effect on GH or IGF-1.

What Sarcotropin Is and Where It Comes From

Origin and product positioning

Sarcotropin is a branded formulation developed by Targeted Medical Pharma (TMP), a California-based company that markets products under the "medical food" regulatory category. The term "medical food" has a specific legal meaning in the United States: under the Orphan Drug Act (1988) and FDA guidance, it refers to a product intended for the dietary management of a disease or condition with distinctive nutritional requirements established by medical evaluation. Medical foods are not required to undergo the randomized controlled trial process required for drug approval. They occupy a regulatory space between dietary supplements and prescription medications, but they are not drugs and carry no FDA-approved efficacy claims.

Sarcotropin is positioned around sarcopenia, the age-related loss of skeletal muscle mass and strength that the EWGSOP2 consensus published in Age and Ageing in 2019 by Cruz-Jentoft and colleagues defined using criteria of low muscle strength, low muscle quantity or quality, and reduced physical performance. Sarcopenia is a legitimate clinical concern with real consequences for functional independence. The product's marketing connects this condition to declining growth hormone and IGF-1 with age, which the biology supports. Junnila, List, Berryman, Murrey, and Kopchick, writing in Nature Reviews Endocrinology in 2013, reviewed the role of the GH-IGF-1 axis in ageing and longevity and documented the progressive decline in pulsatile GH amplitude, mean GH output, and hepatic IGF-1 generation that characterizes the somatopause across most healthy adults. Bartke in a 2019 review in the World Journal of Men's Health, updated this picture with attention to the paradoxes of GH in aging — including evidence that GH signaling is required for normal longevity in some contexts but that elevating GH in already-healthy older adults has not translated into clear functional benefits. The leap from the problem to the product's ability to address it is where the evidence becomes thin.

Active ingredients and proposed mechanism

Sarcotropin's primary active ingredients are amino acids that have been studied as oral growth hormone secretagogues: arginine, lysine, and glutamine. The underlying mechanism is based on arginine's capacity to suppress endogenous somatostatin, thereby releasing the inhibitory brake on pituitary GH secretion, as characterized by Alba-Roth, Müller, Schopohl, and von Werder in a 1988 study in the Journal of Clinical Endocrinology and Metabolism. The formulation also contains polyphenols and other nutritional components, though these are not the primary mechanistic focus of the GH secretagogue claims.

The arginine-lysine combination in particular has a long history in this context. Isidori, Lo Monaco, and Cappa, publishing in Current Medical Research and Opinion in 1981, studied 15 healthy male volunteers and reported that oral administration of 1,200 mg L-lysine combined with 1,200 mg L-arginine pyroglutamate provoked a release of pituitary somatotropin and insulin, while neither amino acid alone at equivalent doses produced meaningful GH stimulation. This small, acute 1981 paper is frequently invoked in Sarcotropin's promotional context. The critical limitations are that it was conducted in young men with a single-dose acute protocol (not chronic supplementation), and — as independent trials below show — the GH response to oral amino acids in older adults is substantially different.

What the Research Shows

Industry-sponsored studies supporting the product

Three published reports directly evaluate Sarcotropin or TMP's amino acid blend, all with TMP investigators in central roles. The earliest was an open-label, single-arm 2019 Endocrine Society conference abstract (SUN-439) by Pekarovics, Romans, Beres, and colleagues published in the Journal of the Endocrine Society Supplement, which reported improvements in IGF-1 and clinical symptoms in participants taking the blend — a conference abstract is not peer-reviewed at the full-article level and is indexed only in meeting supplements, not as a standalone PubMed-listed study. A follow-up 2022 conference abstract by Béres, Kelly, Romans, and colleagues (Journal of the Endocrine Society Supplement, PMON68) reported preliminary results from 84 fibromyalgia patients with low-normal age-adjusted IGF-1 who received the amino acid blend, with a 24-week IGF-1 increase of 28.4 ± 3.0 ng/mL (p < 0.001) and mean weight loss of 5.5 ± 0.3 kg. The most complete published account is a 2023 prospective cohort study by Pekarovics, Beres, Kelly, Billes, and Heaton in Frontiers in Endocrinology examining stress-associated weight gain, fibromyalgia symptoms, and cardiometabolic markers in response to the amino acid blend, with company-affiliated authors acknowledged in the disclosure statement.

All three studies share the same structural limitations: they are industry-sponsored, open-label, and lack a placebo control group. Without a placebo arm, it is not possible to determine whether observed changes reflect the supplement's effects or the natural variation that occurs over time in any observational cohort. These studies are exploratory by design and cannot support efficacy claims. The researchers who published them are affiliated with the company that produces the product.

Independent evidence on arginine, lysine, and GH in older adults

The most directly relevant independent study is a 1993 randomized, placebo-controlled trial by Corpas, Blackman, and colleagues in the Journal of Gerontology that randomized 16 healthy older men (mean age 69 ± 5 years) to 3 g arginine plus 3 g lysine orally twice daily or placebo for 14 days. GH peak amplitude was not significantly altered by treatment, and serum IGF-1 showed no significant change with arginine/lysine versus placebo, while baseline comparisons confirmed older men had lower GH peak amplitude (p < 0.02) and IGF-1 (p < 0.0001) than young controls. This directly tests the arginine-lysine combination at the core of Sarcotropin's mechanism in the exact older-male demographic the product is marketed toward, and the findings contradict the mechanism the product relies on.

Two additional independent studies extend this picture. A 1999 three-trial crossover study by Marcell, Taaffe, Hawkins, and colleagues in the Journal of Gerontology Series A tested 5 g oral arginine, resistance exercise, and the combination in 28 adults (20 young, 8 older) and found that oral arginine neither stimulated resting GH nor augmented the exercise-induced GH response in either age group — and in younger participants the combined arginine-plus-exercise response appeared blunted — contradicting even the more favorable claims about arginine and exercise. A 2005 dose-response crossover study by Collier, Casey, and Kanaley in Growth Hormone and IGF Research in 8 healthy young males (mean age ~25) compared placebo, 5 g, 9 g, and 13 g oral arginine and found GH AUC increased significantly at 5 g (301.5 ± 74.6 min·µg/L) and 9 g (524.3 ± 82.9 min·µg/L) vs. placebo (186.0 ± 47.8 min·µg/L; both p < 0.05), but the 13 g dose produced GI distress and a lower AUC (197.8 ± 65.7) with no additional benefit — and that dose-response relationship was not evaluated in older populations. A 1990 study by Ghigo, Goffi, Arvat, Valente, and colleagues in the Journal of Clinical Endocrinology and Metabolism in 14 subjects (7 elderly and 7 young healthy controls) added an important mechanistic qualifier: while GHRH alone elicited significantly lower GH responses in elderly versus young subjects, co-administration of arginine plus GHRH produced overlapping GH responses in both age groups, with arginine's potentiating effect actually greater in older participants — suggesting the age-related blunting of GH is largely downstream of increased somatostatin tone rather than impaired somatotroph capacity. The small sample and acute intravenous protocol limit extrapolation to chronic oral arginine supplementation.

The literature on amino acid supplementation combined with exercise is similarly mixed. Suminski, Robertson, Goss, and colleagues, in the International Journal of Sport Nutrition in 1997, examined 16 men in a four-trial crossover design (resistance exercise with placebo; 1,500 mg L-arginine plus 1,500 mg L-lysine immediately before exercise; amino acids at rest; placebo at rest) and reported that GH was higher at 30, 60, and 90 minutes during the exercise trials than during the resting trials, with no difference between the two exercise trials, while at rest GH was significantly elevated 60 minutes after amino acid ingestion versus placebo — a modest, acute effect in young men that does not translate to older adults with sarcopenia. Zajac, Poprzecki, Zebrowska, Chalimoniuk, and Langfort, publishing in the Journal of Strength and Conditioning Research in 2010, reported that arginine and ornithine supplementation modestly increased GH and IGF-1 responses after heavy-resistance exercise in strength-trained athletes — a finding in a young, trained population that does not transfer to older adults with sarcopenia. Pushing against even that modest claim, a 2014 randomized double-blind crossover study by Forbes, Harber, and Bell in the International Journal of Sport Nutrition and Exercise Metabolism of 14 strength-trained males found that oral L-arginine (0.075 g/kg body mass) before resistance exercise blunted rather than enhanced the GH response (integrated AUC significantly lower in the arginine condition despite a ~120% rise in plasma arginine), further complicating any simple "amino acids boost GH" claim. For additional physiological context, Kanaley, Weltman, Veldhuis, and colleagues characterized the human GH response to repeated bouts of aerobic exercise in the Journal of Applied Physiology in 1997, establishing the background pulsatile behavior of the GH axis against which any amino acid intervention must be compared.

A 2002 review by Chromiak and Antonio in Nutrition assessed the use of amino acids as GH-releasing agents by athletes and concluded that oral efficacy claims are largely overstated relative to intravenous data. Intravenous arginine reliably stimulates GH; oral administration produces far more variable and generally weaker results, particularly in older individuals whose pituitary GH reserve is already diminished. The 2008 narrative review by Kanaley in Current Opinion in Clinical Nutrition and Metabolic Care reached a similar conclusion, noting that while arginine and exercise interact with GH secretion, the available data did not support amino acid supplementation as a meaningful GH-raising strategy. The joint position of the American Dietetic Association, Dietitians of Canada, and the American College of Sports Medicine, published by Rodríguez, DiMarco, and Langley in the Journal of the American Dietetic Association in 2009, takes a similar line: dietary and amino acid supplementation strategies can support training adaptations in specific contexts, but the evidence does not support individual amino acids as reliable anabolic or GH-releasing agents in trained or untrained populations.

Glutamine and glycine: mixed evidence

Glutamine, another ingredient in the Sarcotropin formulation, received attention in the 1990s as a potential oral GH secretagogue. A 1995 study by Welbourne in the American Journal of Clinical Nutrition administered a single 2 g oral glutamine load to 9 healthy adults and reported elevated plasma bicarbonate and circulating GH at 90 minutes in 8 of 9 subjects — a small, acute, uncontrolled observation, not a chronic supplementation trial. A 2003 randomized placebo-controlled study by Arwert, Deijen, and Drent in Nutritional Neuroscience gave 42 middle-aged and elderly subjects (14 men, 28 women, ages 40–76) 5 g of an oral glycine/glutamine/niacin mixture or placebo twice daily for 3 weeks and reported a 70% relative increase in serum GH versus placebo (from 3.23 to 4.67 mU/L) while IGF-1 did not change significantly overall. Both studies involved small samples, and neither was conducted using Sarcotropin's full proprietary formulation under controlled conditions. The evidence from these studies is hypothesis-generating, not confirmatory.

What this evidence base means in context

The cumulative picture from the independent literature is one of theoretical plausibility combined with weak and largely negative human evidence in the populations most likely to use this product. Amino acids can influence GH secretion in certain conditions, at certain doses, and in certain populations. In older adults, who represent the primary market for a sarcopenia-focused product, the most methodologically rigorous independent trial found no effect from the Sarcotropin combination. The three industry-sponsored studies cannot be weighted equally with well-controlled independent research.

Sarcotropin vs. Prescription GHRH Analogs: A Research Context Comparison

Sarcotropin is frequently discussed alongside prescription growth hormone secretagogues: compounds like sermorelin, tesamorelin, and CJC-1295 that act directly on pituitary GHRH receptors. This comparison is useful for calibrating the evidence gap. It is not a clinical equivalence argument. These compounds have fundamentally different regulatory statuses, mechanisms of action, and evidence bases.

A pivotal 412-patient double-blind randomized controlled trial by Falutz, Allas, and colleagues in the New England Journal of Medicine in 2007 demonstrated that tesamorelin 2 mg daily for 26 weeks reduced visceral adipose tissue by 15.2% versus a 5.0% increase with placebo (p < 0.001), establishing the FDA-approved indication for HIV-associated lipodystrophy. Sermorelin, a 29-amino-acid synthetic peptide identical to the first 29 residues of endogenous GHRH, directly binds pituitary GHRH receptors and has been studied in the compounding market for age-related GH decline. A 2006 JCEM study by Teichman, Neale, Lawrence, and colleagues demonstrated that CJC-1295 produced sustained GH and IGF-1 elevation in healthy adults over multiple weeks. In the parallel growth hormone secretagogue class, Raun, Hansen, Johansen, and colleagues characterized ipamorelin as the first selective growth hormone secretagogue in the European Journal of Endocrinology in 1998, demonstrating potent and highly selective GH release in rats and swine without the concurrent elevations in ACTH, cortisol, or prolactin that limit less selective agents — a characterization that continues to anchor the scientific comparison class for any compound claiming to elevate GH.

A landmark 2007 systematic review and meta-analysis by Liu, Bravata, and colleagues in the Annals of Internal Medicine pooled 220 participants across 18 unique study populations (107 person-years of GH exposure) receiving growth hormone replacement and found modest body composition changes (fat mass -2.1 kg, lean mass +2.1 kg) with no significant weight change, but significantly higher rates of soft-tissue edema, arthralgia, carpal tunnel syndrome, gynecomastia, new-onset diabetes, and impaired glucose tolerance — concluding that evidence was insufficient to recommend GH as an anti-aging intervention in healthy elderly adults. A much larger long-term safety observation came from Johannsson, Høybye, Jorgensen, and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2022, who analyzed pooled safety data from 15,809 adults with growth hormone deficiency receiving long-term GH replacement. The analysis characterized the event rates for malignancy, diabetes, and cardiovascular endpoints in a population with a defined clinical indication for therapy, and provides the contemporary reference against which off-label, unproven strategies for "boosting GH" in otherwise healthy older adults should be calibrated. This context is important: even if Sarcotropin successfully raised GH to the levels achieved by prescription analogs (for which no evidence exists), a meaningful clinical benefit in healthy older adults is not guaranteed, and the risk-benefit profile of GH-elevating approaches in this population requires careful evaluation. This comparison is provided for scientific context only. Prescription GHRH analogs and Sarcotropin have fundamentally different regulatory statuses and evidence bases, and any prescribing of GHRH analogs represents the independent clinical judgment of a licensed provider.

Safety: What Is and Is Not Known

Safety profile of the active ingredients

Arginine, lysine, and glutamine are common amino acids present in standard dietary protein and have well-established safety profiles at nutritional doses. The primary reported adverse effect of high-dose oral arginine is gastrointestinal disturbance: nausea, cramping, and diarrhea, observed at higher doses in the Collier 2005 study and consistent with the general literature on large amino acid loads. These are not serious adverse events, but they limit dose escalation. No serious safety signals specific to the Sarcotropin formulation have been published in peer-reviewed literature, which is consistent with the benign safety profile of its constituent amino acids. The absence of documented harm is not the same as established safety data from controlled trials.

Regulatory transparency and the "medical food" designation

Because Sarcotropin is marketed as a medical food rather than a drug, it was not required to demonstrate efficacy through randomized controlled trials before going to market. The FDA does not pre-approve medical foods, and the medical food category does not require the same level of clinical evidence as a New Drug Application. Products in this category can be marketed with therapeutic-sounding language (including disease references) without meeting the FDA's drug efficacy standards. The FDA's own Guidance for Industry: Frequently Asked Questions About Medical Foods (Third Edition, 2016) details the narrow statutory definition and explicitly states that FDA does not pre-approve medical foods, clarifying the regulatory ambiguities that make this category practically difficult to adjudicate. The broader supplement regulatory picture has its own documented failure modes: Tucker, Fischer, Upjohn, Mazzera, and Kumar, publishing in JAMA Network Open in 2018, analyzed 776 adulterated dietary supplements identified through FDA warnings from 2007 through 2016 across 146 companies and found that 45.5% were sexual enhancement products, 40.9% were weight loss products, and 11.9% were muscle-building products, with sibutramine detected in 84.9% of adulterated weight loss supplements and synthetic steroids in 89.1% of adulterated muscle-building products — documenting that products sold outside the drug-approval pathway have repeatedly contained undeclared active pharmaceutical ingredients despite their OTC supplement or medical-food positioning. That track record does not itself implicate Sarcotropin, but it underscores why the regulatory pathway matters when evaluating any product that makes physiological claims without drug-level review. Consumers evaluating medical food products should understand that the regulatory pathway is meaningfully different from drug approval.

Who Should Not Use Sarcotropin

Based on the compound's proposed mechanism of stimulating growth hormone secretion and the theoretical considerations associated with that mechanism, the following groups face elevated theoretical risk.

• Individuals with active or suspected malignancy, particularly cancers where IGF-1 pathway activity may influence tumor behavior (including prostate, breast, and colorectal), given the product's stated goal of raising GH and IGF-1 levels
• Individuals with acromegaly or other conditions associated with excess GH or IGF-1 activity, for whom further GH stimulation is contraindicated
• Individuals with renal impairment, for whom high-dose amino acid supplementation may place additional burden on protein metabolism and filtration; baseline kidney function should be evaluated before any high-dose amino acid regimen
• Pregnant or breastfeeding individuals: safety during pregnancy and lactation has not been studied for this product or formulation
• Individuals taking medications that affect GH secretion or amino acid metabolism, given the potential for additive or antagonistic interactions not studied in this product's limited trial base

This is not a complete list. Anyone considering Sarcotropin should discuss their full medical history and medication list with a qualified healthcare provider before use.

Which Biomarkers Are Relevant if You Are Exploring GH Axis Biology?

For anyone investigating the GH-IGF-1 axis, whether as context for evaluating sarcopenia, age-related body composition changes, or supplements like Sarcotropin, objective measurement is a more informative starting point than uncontrolled symptom tracking.

• IGF-1: The most practical serum marker for overall growth hormone axis activity. Because GH itself is secreted in pulses and is difficult to capture reliably with a single draw, the liver's IGF-1 output serves as an integrated surrogate. A guide to interpreting IGF-1 in the context of aging and longevity provides additional context on what levels mean across age groups.
• hs-CRP: Chronic low-grade inflammation is both a driver and a consequence of sarcopenia. High-sensitivity C-reactive protein provides a sensitive measure of background inflammatory activity, relevant because some of the symptom improvements reported in TMP's open-label studies (fatigue, fibromyalgia symptoms) could plausibly reflect changes in inflammatory tone rather than GH axis effects.
• Albumin: A marker of nutritional status and visceral protein stores. In older adults, low albumin is a well-established indicator of protein-calorie malnutrition and correlates with muscle wasting. Any intervention targeting sarcopenia should be evaluated against an albumin baseline, since protein status may confound response to amino acid supplementation.
• Creatinine and eGFR: Baseline kidney function is relevant before starting high-dose amino acid supplementation. Creatinine and estimated glomerular filtration rate provide the context needed to assess whether amino acid loads are appropriate for an individual's renal reserve.
• Fasting glucose and HbA1c: GH promotes insulin resistance, and products marketed to raise GH may affect glucose regulation in susceptible individuals. A fasting glucose and HbA1c baseline is a reasonable precaution before any GH-focused intervention.
• Testosterone (in men): Testosterone and GH influence overlapping body composition pathways. In men with sarcopenia, low testosterone is a more commonly investigated and better-evidenced contributor to muscle loss than GH insufficiency. A full hormonal baseline that includes testosterone prevents conflating these separate causes.

When to Take This Seriously

Sarcopenia is a legitimate clinical concern that warrants objective evaluation. The muscle loss, functional decline, and cardiometabolic consequences of progressive sarcopenia are documented at a population level. A 2014 epidemiology update by Morley, Anker, and von Haehling in the Journal of Cachexia, Sarcopenia and Muscle documented sarcopenia prevalence estimates of 5 to 13 percent in adults aged 60 to 70 and 11 to 50 percent in those over 80. If you are experiencing unexplained muscle weakness, fatigue, or functional decline, established clinical evaluation pathways exist. A primary care provider or geriatrician can assess muscle function, body composition, and relevant laboratory markers. The GH-IGF-1 axis, inflammatory markers, nutritional status, sex hormones, and glucose metabolism are all measurable with standard blood panels, and they provide the objective context that any clinical decision should start from.

The clinical reality is that declining IGF-1 with age is one contributor to sarcopenia among several. Understanding where your markers actually sit is more informative than assuming what they might be. That principle of objective measurement before intervention is what Superpower was built around, articulated in the Superpower approach to preventive health: knowing your baseline is the foundation for evaluating any clinical or supplemental option rationally.

IMPORTANT SAFETY INFORMATION

Sarcotropin is not FDA-approved for any indication. It is marketed as a "medical food" by Targeted Medical Pharma and is not subject to the FDA drug approval process. Superpower Health does not prescribe, sell, or facilitate access to Sarcotropin. Superpower is a technology platform connecting members with licensed providers and laboratory services; it does not manufacture, distribute, or endorse Sarcotropin or any other Targeted Medical Pharma product.

No placebo-controlled randomized clinical trial of Sarcotropin has been published as of April 2026. All published studies directly evaluating the product or its proprietary amino acid blend are open-label, industry-sponsored, and uncontrolled. The most methodologically rigorous independent study of the product's primary active ingredients (oral arginine-lysine) in older men found no effect on GH or IGF-1 levels. The evidence base does not meet the standard required to establish efficacy.

Theoretical contraindications based on proposed mechanism: active or suspected malignancy where IGF-1 pathway activity may influence tumor behavior; acromegaly or conditions involving excess GH; significant renal impairment (high-dose amino acid supplementation may affect protein metabolism and kidney filtration load).

Warnings: high-dose oral arginine may cause gastrointestinal distress (nausea, cramping, diarrhea); individuals with diabetes or glucose dysregulation should monitor glucose when using products marketed to raise GH; individuals on medications affecting GH secretion or amino acid metabolism should consult a provider before use; the "medical food" regulatory designation does not imply FDA-reviewed efficacy.

The safety profile described above reflects the constituent amino acid ingredients, not Sarcotropin as a proprietary formulation evaluated in controlled trials. Long-term safety data for this specific product at therapeutic doses is not available from published controlled research.

This is not a complete summary of risks. No FDA-approved prescribing information exists for Sarcotropin. Regulatory and labeling information should be verified directly with the manufacturer and at FDA.gov.

Additional Questions

Is Sarcotropin safe?

The active ingredients in Sarcotropin, including arginine, lysine, and glutamine, are common dietary amino acids with well-established safety profiles at nutritional doses. High-dose oral arginine can cause gastrointestinal distress. No serious adverse events specific to Sarcotropin have been published. The absence of documented harm reflects both the benign nature of the amino acid ingredients and the limited scope of the published research, not an established clinical safety profile from controlled trials.

What is the difference between Sarcotropin and a growth hormone supplement?

Sarcotropin contains amino acid precursors that its manufacturer claims support GH secretion indirectly. It does not contain growth hormone itself, which cannot be taken orally because it is a protein that digestive enzymes would degrade before absorption. Products that actually contain human growth hormone are prescription-only injectable medications. The distinction matters because the mechanism and evidence standard for an oral amino acid blend and a prescription GH preparation are entirely different.

Are there biomarkers I can test to assess my GH axis?

Yes. IGF-1 is the most clinically useful serum marker for growth hormone axis activity in routine practice. It integrates pulsatile GH secretion over time and provides an age-adjusted reference range that reflects where an individual stands relative to peers. For the broader context of muscle health and body composition, inflammatory markers, nutritional markers including albumin, and sex hormones round out the relevant panel. Reference ranges vary by laboratory and age; a qualified provider will interpret your specific results in context.

What does "medical food" mean, and is it regulated?

A medical food is a product intended for the dietary management of a disease or condition with distinctive nutritional requirements, as defined under the Orphan Drug Act (1988). Medical foods are not pre-approved by the FDA and do not require the same clinical trial evidence as prescription drugs. They may be labeled with disease references without meeting the drug efficacy standard. The medical food designation gives products like Sarcotropin a more clinical appearance than standard supplements without requiring the evidence base that a prescription drug must provide.